WO2023067505 - 2-FLUORODESCHLOROKETAMINE FOR TREATMENT OF DEPRESSION, INCLUDING TREATMENT-RESISTANT DEPRESSION
National phase entry:
Publication Number
WO/2023/067505
Publication Date
27.04.2023
International Application No.
PCT/IB2022/060011
International Filing Date
18.10.2022
Title **
[English]
2-FLUORODESCHLOROKETAMINE FOR TREATMENT OF DEPRESSION, INCLUDING TREATMENT-RESISTANT DEPRESSION
[French]
2-FLUORODESCHLOROKÉTAMINE POUR LE TRAITEMENT DE LA DÉPRESSION, Y COMPRIS LA DÉPRESSION RÉSISTANTE AU TRAITEMENT
Applicants **
CLEARMIND MEDICINE INC.
20 Raoul Wallenberg Street
Building A, 2nd Fl.
Tel Aviv, IL
Inventors
GOLAN, Ezekiel
1120 Ironwork Passage
Vancouver, British Columbia V6H 3P1, CA
Priority Data
63/256,728
18.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1178 | |
| EPO | Filing, Examination | 5566 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2710 |
Total: 10618 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that administering 2-fluorodeschloroketamine (2-FDCK) is effective to treat depression, especially to treat treatment-resistant depression.[French]
L'invention concerne des procédés et des compositions pour le traitement de la dépression résistante au traitement. Plus spécifiquement, l'invention démontre que l'administration de 2-fluorodeschlorokétamine (2-FDCK) est efficace pour traiter la dépression, en particulier pour traiter la dépression résistante au traitement.